Shilpa Gupta
@shilpaonc
GU oncologist, clinical trialist. Director, GU Oncology @CleclinicMD Tweets my own, RT/Likes not active endorsement.
Just in @TheLancetOncol The PROs from the EV-302 trial, which led to the global approval of 1L EV+pembro in mUC 👉EV+P led to clinically meaningful pain relief, esp. in pts with moderate-severe baseline pain 👉EV+P led to better EORTC QLQ-C30 functioning and QoL improvements…
Thank you! Great to meet you and learn about all the advances over different cancer types.
Could not think of a better person to take on this tremendous role for this @AmericanCancer journal! Congrats @DrRanaMcKay! @DrChoueiri @BradMcG04 @shilpaonc @VivekSubbiah @neerajaiims @PGrivasMDPhD
Please join us in welcoming @DrRanaMcKay as our new Section Editor for Genitourinary Disease! Dr. McKay is a medical oncologist who specializes in treating people with urogenital cancers. Her research interests include precision medicine and biomarker development. @OncoAlert
After spending time w yet another amazing @ASCO LDP class (my small group: @nabiladra, @umangtalking, #DrRebeccaSnyder, #DrCiaraOSullivan), capitalized on @NRGonc happening in the DC area & met up w former LDP classmate @ndenduluri1, former LDP mentees @shilpaonc & @StephenChunMD…
I felt surrounded by brilliant, innovative, patient centered colleagues today. Thank you all for coming to DC
Incredibly proud and grateful for the success of this @NRGonc ADC Symposium in DC! Packed room, outstanding talks from all faculty, and plenty of food for thought to push forward the field of ADC across oncology fields.
Thanks @DrKatyMoore @PTarantinoMD for organizing such a state of the art session on everything about ADCs across solid tumors and the invite to talk about ADCs in GU cancers! What an incredible session with an all ⭐️ faculty with the best part being the realistic and poignant…
Incredibly proud and grateful for the success of this @NRGonc ADC Symposium in DC! Packed room, outstanding talks from all faculty, and plenty of food for thought to push forward the field of ADC across oncology fields.
ADC biomarkers are complex! @BiagioRicciutMD from @DanaFarber provides an outstanding overview of the lessons learned in thoracic oncology, highlighting challenges with predicting which patients actually benefit of specific ADCs. @NRGonc
Bringing #Hollywood to #Boston in this high budget trailer for the #Uromigos25 meeting this fall. @tompowles1 has put his heart & soul into designing the T-shirts you see below, and #McDermott has been investing in acting classes. Enjoy my directorial debut & ❤️the post 👇 to…
This year’s Uromigos Cup is America 🇺🇸 🇨🇦 vs Eurasia 🇯🇵 🇨🇳 🇦🇺 🇪🇺 . Eurasia is already 1-0 ahead after winning the darts 🎯 at the Uromigos party. Here @montypal starts to pick his americas team in this multidisciplinary and wide ranging competition. It will finish at the…
This year’s Uromigos Cup is America 🇺🇸 🇨🇦 vs Eurasia 🇯🇵 🇨🇳 🇦🇺 🇪🇺 . Eurasia is already 1-0 ahead after winning the darts 🎯 at the Uromigos party. Here @montypal starts to pick his americas team in this multidisciplinary and wide ranging competition. It will finish at the…
Congrats to all the newly elected @ASCO FASCO members! Great to see so many friends and colleagues on this list! @DrYukselUrun @apolo_andrea @umangtalking @WalterStadler5 @IbiayiMD @TiansterZhang and so many others.
Join us in congratulating the following members on earning the Fellows of ASCO (FASCO) distinction last quarter! We are grateful for their extraordinary volunteer service, dedication, and commitment to ASCO. Learn more about FASCO distinction: brnw.ch/21wUiVu
✨ 100% benefit rate, but who actually gets access? In the latest episode of #OncologyUnscripted, Dr. @marshalj23 dives into why smarter cancer care isn’t just about innovation, it’s about access, equity, and value. From IO therapy for MSI+ rectal cancer to inexpensive…
Celebrating the winners of the KCRS25 Merit Awards for Clinical Research! 👏 Dr. Yu-wei Chen, University of California San Diego 👏 Dr. Koral Shah, City of Hope 👏 Ruchi Agarwal, University of Pennsylvania #KCRS25 #AcceleratingCures
We need to randomise in papillary RCC #KCRS25 @montypal .Single arm trials can be misleading. ⏩️ Stellar304 (Zanza+nivo vs sun) & SAMETA (Savo+durva vs sun). Global access to VEGF/PD1 combos is limited due to weak single arm data. To change global practice we need to randomise
Great line up for trials in progress kicked off by @NazliDizman on ivonescimab (bispecific anti PD-1 and VEGF) in RCC @kidneycan #KCRS25
Congrats to @bilenma @WinshipAtEmory for utilizing @theNCI cooperative groups for what they are best at - addressing clinically relevant questions for agents already in our toolkit. Excited to support the study he & @NaomiHaas5 @PennCancer have put forward via @eaonc looking at…
1st and 2nd line therapy #KCRS25 . VEGF/HIF and PD1/CTLA4 together or sequenced have largely been explored from adjuvant to 2nd, improving outcomes. Unexplored areas include HIF combos, new HIF (casdatifan), KIM1/PDL1 biomarkers. Triplet therapy & TIGIT/LAG3 etc have struggled.
Many thanks to @NaomiHaas5 @PennCancer for discussing @WesleyYipMD @cityofhope's adjuvant trial of pembro + #CBM588 - the subject of his @ASCO CDA! Terrific session at #KCRS25.
Proud of @ruchia_upenn, a @Penn undergraduate who spent her summers working with us at @cityofhope. Today she presented her work with @ReginaBarCar @incanMX on international #kidneycancer trial availability - so impressive!
Wonderful presentation by @ruchia_upenn highlighting global disparities in clinical trial availability for RCC. A crucial reminder of the inequities that persist and the urgent need for more inclusive research efforts. #KCRS25
Year 7 of @kidneycan #KCRS2025 and it all started with my co-chair @HHammersMD !